Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AXSM NASDAQ:ETNB NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$69.86-2.9%$27.70$4.77▼$75.51$5.43B0.563.25 million shs1.42 million shsAXSMAxsome Therapeutics$109.39+4.0%$105.71$75.56▼$139.13$5.25B0.51630,955 shs589,197 shsETNB89BIO$9.14+1.1%$9.93$4.16▼$11.84$1.34B1.281.46 million shs2.09 million shsNUVLNuvalent$78.24+2.1%$78.94$55.53▼$113.51$5.50B1.3517,548 shs284,968 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-2.86%+1.11%+691.12%+1,066.21%+537.37%AXSMAxsome Therapeutics+3.95%+5.94%-2.62%+2.02%+28.92%ETNB89BIO+1.11%-3.59%-17.81%+19.63%+13.97%NUVLNuvalent+2.13%+1.31%-7.51%+10.20%+9.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax3.7504 of 5 stars4.64.00.00.03.30.80.6AXSMAxsome Therapeutics4.8221 of 5 stars4.53.00.04.52.54.20.6ETNB89BIO1.9638 of 5 stars3.52.00.00.01.80.80.6NUVLNuvalent3.1031 of 5 stars4.51.00.00.02.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.3332.18% UpsideAXSMAxsome Therapeutics 3.07Buy$178.0062.72% UpsideETNB89BIO 3.00Buy$26.29187.59% UpsideNUVLNuvalent 3.09Buy$119.6052.86% UpsideCurrent Analyst Ratings BreakdownLatest ETNB, NUVL, ABVX, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025ETNB89BIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $11.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.008/4/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$150.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.007/29/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/23/2025ABVXAbivaxLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$74.007/23/2025ABVXAbivaxLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$45.00 ➝ $101.007/23/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $70.007/23/2025ABVXAbivaxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $101.007/23/2025ABVXAbivaxMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$71.00(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAXSMAxsome Therapeutics$385.69M14.15N/AN/A$1.46 per share74.92ETNB89BION/AN/AN/AN/A$3.52 per shareN/ANUVLNuvalentN/AN/AN/AN/A$13.09 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAXSMAxsome Therapeutics-$287.22M-$5.07N/A38.79N/A-49.88%-283.22%-33.06%N/AETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%N/ANUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%8/14/2025 (Estimated)Latest ETNB, NUVL, ABVX, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25AXSMAxsome Therapeutics1.661.571.51ETNB89BIO0.0715.1918.03NUVLNuvalentN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AXSMAxsome Therapeutics81.49%ETNB89BION/ANUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAXSMAxsome Therapeutics22.30%ETNB89BIO2.60%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.55 millionN/ANot OptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableNUVLNuvalent4071.81 million64.48 millionOptionableETNB, NUVL, ABVX, and AXSM HeadlinesRecent News About These CompaniesNuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential SymposiumAugust 13 at 1:06 PM | prnewswire.comWedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)August 11 at 2:43 AM | marketbeat.comInsider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 5,500 Shares of StockAugust 10, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 5,500 SharesAugust 9, 2025 | insidertrades.comNuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | prnewswire.comNuvalent (NUVL) Projected to Post Quarterly Earnings on ThursdayAugust 7, 2025 | americanbankingnews.comNuvalent (NUVL) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comXTX Topco Ltd Acquires New Stake in Nuvalent, Inc. (NASDAQ:NUVL)August 5, 2025 | marketbeat.comJefferies Financial Group Inc. Acquires 23,795 Shares of Nuvalent, Inc. (NASDAQ:NUVL)August 4, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Buy" by BrokeragesAugust 4, 2025 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Buy" by BrokeragesAugust 4, 2025 | marketbeat.comTD Asset Management Inc Purchases 23,412 Shares of Nuvalent, Inc. (NASDAQ:NUVL)August 3, 2025 | marketbeat.comNuvalent (NUVL) Gets a Buy from Goldman SachsJuly 30, 2025 | theglobeandmail.comVictory Capital Management Inc. Has $1.88 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL)July 30, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Sells 11,308 Shares of Nuvalent, Inc. (NASDAQ:NUVL)July 29, 2025 | marketbeat.comNuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLCJuly 25, 2025 | msn.comLegato Capital Management LLC Has $629,000 Holdings in Nuvalent, Inc. (NASDAQ:NUVL)July 25, 2025 | marketbeat.comNew York State Common Retirement Fund Buys 3,965 Shares of Nuvalent, Inc. (NASDAQ:NUVL)July 25, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Given Outperform Rating at WedbushJuly 21, 2025 | marketbeat.comNuvalent Initiates Phase 3 ALKAZAR Clinical TrialJuly 21, 2025 | tipranks.comNuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLCJuly 21, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETNB, NUVL, ABVX, and AXSM Company DescriptionsAbivax NASDAQ:ABVX$69.86 -2.05 (-2.86%) Closing price 08/13/2025 03:59 PM EasternExtended Trading$69.81 -0.04 (-0.06%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Axsome Therapeutics NASDAQ:AXSM$109.39 +4.16 (+3.95%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$107.47 -1.92 (-1.76%) As of 08/13/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.89BIO NASDAQ:ETNB$9.14 +0.10 (+1.11%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$9.14 -0.01 (-0.05%) As of 08/13/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Nuvalent NASDAQ:NUVL$78.24 +1.63 (+2.13%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$78.28 +0.04 (+0.04%) As of 08/13/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.